GRAY Graybug Vision, Inc.

Graybug Vision, Inc. is a clinical-stage biopharmaceutical company focused on developing transformative medicines to treat chronic vision-threatening diseases of the retina and optic nerve.

$0.98
As of 07/01/2022     IEX book   CBOE book

---

Security Information

---

Category1:  US Equity
Category2:  Common stocks
Category3:  Micro cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  USA
IPO date:  09/25/2020
Outstanding shares:  21,362,773
Average volume:  860,538
Market cap:   $23,285,423
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
Sedol:      

---

Valuation   (See tab for details)

---

PE ratio:   0.00
PB ratio:   0.37
PS ratio:   0.00
Return on equity:   -61.36%
Net income %:   0.00%